SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Incyte (INCY) -- Ignore unavailable to you. Want to Upgrade?

To: Rocketman who wrote (768)11/4/1998 12:26:00 PM
From: Mike McFarland  Read Replies (1) | Respond to of 3202
 
So, Incyte has patents pending which cover 1.2M EST sequences,
and the first patent for a set of EST's which cover 44 protein
kinases was just issued. I think I got that right.

So is 1.2M a very large number of EST sequences? There are an
awful lot up for grabs still. Is 44 an impressive number of PK's
to have in a single patent? Which companies are the runners up in
the race? (And finally, why the hell have I been sitting on shares
of Hyseq and Ariad when I could have been making money along with
all of you? Being a contrarian in stocks can be very costly...)

--MM



To: Rocketman who wrote (768)11/4/1998 12:28:00 PM
From: Vector1  Read Replies (2) | Respond to of 3202
 
<<This is great stuff!!!>>

Yes it is. I wonder if they are going to issue a press release each time a new EST patent is issued. If so they are going to be issuing press releases every other day. I think we are looking at a solid run to $40.
V1


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News